Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JOURNAL OF HEMATOLOGY & ONCOLOGY13(1) · 2020
- 피인용
- Web of Science 39Scopus 40
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 11.059
- ISSN
- 1756-8722
저자
- Weisel, Katja제1저자교신저자Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf Hamburg Germany
- Spencer, Andrewgrid.267362.4 0000 0004 0432 5259 Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University Melbourne Australia
- Lentzsch, Suzannegrid.21729.3f 0000000419368729 Division of Hematology/Oncology, Columbia University New York, NY USA
- Avet-Loiseau, Hervégrid.414295.f 0000 0004 0638 3479 Unite de Genomique du Myelome, CHU Rangueil Toulouse France
- Mark, Tomer M.grid.430503.1 0000 0001 0703 675X Department of Medicine, University of Colorado Aurora, CO USA
- Spicka, Ivangrid.4491.8 0000 0004 1937 116X Clinical Department of Haematology, 1st Medical Department, Charles University in Prague Prague Czech Republic
- Masszi, Tamasgrid.11804.3c 0000 0001 0942 9821 László Hospital, 3rd Department of Internal Medicine, Semmelweis University Budapest Hungary
- Lauri, BirgittaDepartment of Hematology, Sunderbyn Hospital Luleå Sweden
- Levin, Mark-Davidgrid.413972.a 0000 0004 0396 792X Department of Internal Medicine, Albert Schweitzer Hospital Dordrecht The Netherlands
- Bosi, Albertogrid.8404.8 0000 0004 1757 2304 Department of Hematology, Careggi Hospital and University of Florence Firenze Italy
- Hungria, Vaniagrid.419432.9 0000 0000 8872 5006 Irmandade Da Santa Casa De Misericordia De Saõ Paulo Saõ Paulo Brazil
- Cavo, Michelegrid.6292.f 0000 0004 1757 1758 "Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna Bologna Italy
- Lee, Je-Junggrid.411602.0 0000 0004 0647 9534 Department of Hematology-Oncology, Chonnam National University Hwasun Hospital Hwasun, Jeollanamdo South Korea
- Nooka, Ajaygrid.189967.8 0000 0001 0941 6502 Winship Cancer Institute, Emory University Atlanta, GA USA
- Quach, Hanggrid.413105.2 0000 0000 8606 2560 University of Melbourne, St Vincent's Hospital Melbourne Australia
- Munder, Markusgrid.410607.4 University Medical Center of the Johannes Gutenberg University, Third Department of Medicine Mainz Germany
- Lee, Cindygrid.416075.1 0000 0004 0367 1221 Royal Adelaide Hospital North Terrace Adelaide Australia
- Barreto, Wolneygrid.11899.38 0000 0004 1937 0722 University of Saõ Paulo Ribeiraõ Preto Brazil
- Corradini, Paologrid.4708.b 0000 0004 1757 2822 Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan Milan Italy
- Min, Chang-Kigrid.414966.8 0000 0004 0647 5752 Seoul St. Mary's Hospital Seoul South Korea
- Chanan-Khan, Asher A.grid.417467.7 0000 0004 0443 9942 Mayo Clinic Florida Jacksonville, FL USA
- Horvath, Noemigrid.416075.1 0000 0004 0367 1221 Royal Adelaide Hospital North Terrace Adelaide Australia
- Capra, Marcelogrid.414871.f 0000 0004 0491 7596 Instituto do Cancer-Hospital Mae de Deus Porto Alegre Brazil
- Beksac, Meralgrid.7256.6 0000000109409118 Ankara University Ankara Turkey
- Ovilla, RobertoHospital Angeles Lomas Naucalpan de Juárez y alrededores Mexico
- Jo, Jae-Cheolgrid.412830.c 0000 0004 0647 7248 Ulsan University Hospital Ulsan South Korea
- 신호진grid.412588.2 0000 0000 8611 7824 Department of Internal Medicine, Pusan National University Hospital Busan South Korea
- Sonneveld, Pietergrid.5645.2 000000040459992X Erasmus MC Rotterdam The Netherlands
- Casneuf, Tinekegrid.419619.2 0000 0004 0623 0341 Janssen Research & Development, LLC Beerse Belgium
- Deangelis, Nikkigrid.419619.2 0000 0004 0623 0341 Janssen Research & Development, LLC Beerse Belgium
초록
Background: Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). Methods: This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10(-5)sensitivity threshold) was assessed via the clonoSEQ (R) assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk. Results: After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37;P< 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21-0.83;P= 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR. Conclusion: These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status.
키워드
Clinical trialsMultiple myelomaMyeloma therapyINTERGROUPE FRANCOPHONEANTIBODY DARATUMUMABSURVIVALABNORMALITIESCONSENSUS
식별자
- Scopus EID
- 2-s2.0-85089769416
- WoS UID
- 000566236600001



로그인
연구물 목록으로